Loading clinical trials...

RECRUITINGPHASE2

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer: A Double Blind, Placebo Controlled, Phase II Randomized Controlled Trial

NCT05849129•The Canadian College of Naturopathic Medicine

View on ClinicalTrials.gov

Summary

This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer
•2. Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy

Exclusion Criteria

•1. ECOG status greater than 2
•2. Previously received IVC within 6 months prior to randomization
•3. Biochemical deficiency in G6PD
•4. Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min
•5. Currently taking insulin or warfarin
•6. History of severe renal dysfunction or hemochromatosis
•7. Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
•8. If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency
•9. Currently taking an investigational product or participation in an investigational study within the past 30 days
•10. Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating

Locations (1)

The Ottawa Hospital

Ottawa, Ontario, Canada

Key Dates

Start Date

October 1, 2024

Primary Completion Date

October 1, 2030

Completion Date

October 1, 2031

Last Updated

January 23, 2026

Enrollment

ESTIMATED participants

Conditions

Lung Cancer

Interventions

Ascorbic acid

DRUG

Normal Saline

OTHER

Contacts

Dugald Seely, ND, MSc

CONTACT

613-792-1222 dseely@thechi.ca

Mark Legacy, BSc, CCRP

CONTACT

613-792-1222 mlegacy@thechi.ca

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

RECRUITING

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Magnetic Resonance Imaging of the Lung: Oncological Applications

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer